Mastócitos e síndrome de ativação mastocitária: o que há de novo?
Mast cells and mast cell activation syndrome: what’s new?
Sofia Couto; Tiago Rama; Catarina Martins; Luís Miguel Borrego
Resumo
Os mastócitos são as principais células efetoras da resposta alérgica aguda, desempenhando também um papel importante na angiogênese, tolerância imunológica, regulação da fibrinólise, regeneração neuronal e osteoclastogênese. Localizam-se maioritariamente na pele e nas mucosas do intestino e pulmões, onde exercem uma função “sentinela”. As síndromes de ativação mastocitária são caracterizadas pela ocorrência de episódios recorrentes de manifestações clínicas resultantes da libertação de mediadores mastocitários. Esta constitui-se como entidade complexa com um espectro de sintomas associados, representando um desafio diagnóstico e terapêutico. Nesta revisão, os autores pretendem apresentar uma visão geral sobre a estrutura e função dos mastócitos e sobre os critérios diagnósticos e abordagem terapêutica da síndrome de ativação mastocitária.
Palavras-chave
Abstract
Mast cells are the main effector cells of acute allergic response, also playing an important role in angiogenesis, immune tolerance, regulation of fibrinolysis, neuronal regeneration, and osteoclastogenesis. They are generally located in the skin and mucous membranes of the intestines and lungs, where they perform a “sentinel” function. Mast cell activation syndrome is characterized by recurrent clinical manifestations resulting from the release of mast cell mediators. This complex entity, which involves a spectrum of associated symptoms, is a diagnostic and therapeutic challenge. In this article we overview of the structure and function of mast cells, in addition to the diagnostic criteria and therapeutic approaches to mast cell activation syndrome.
Keywords
References
1. Castells M, Butterfield J. Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management. J Allergy Clin Immunol Pract. 2019;7:1097-106.
2. Afrin LB, Ackerley MB, Bluestein LS,Brewer JH, Brook JB, Molderings G, et al. Diagnosis of mast cell activation syndrome: a global "consensus-2". De Gruyter. 2020:1-16.
3. Adkinson N, Bochner B, Burks AW, Busse WW, Holgate ST, Lemanske RF, et al. Middleton's Allergy: principles and practices. 8ª ed. Elsevier Inc.; 2013. p. 1896.
4. Gülen T, Akin C, Bonadonna P, Siebenhaar F, Broesby-Olsen S, Brockow K, et al. Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review. J Allergy Clin Immunol Pract. 2021 Nov;9(11):3918-28.
5. Valent P, Akin C, Escribano L, Fodinger M, Hartmann K, Brockow K, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 2007;37:435-53.
6. Alvarez-Twose I, Jara-Acevedo M, Morgado JM, Garcia-Montero A, Sanchez-Munoz L, Teodosio C, et al. Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis. J Allergy Clin Immunol. 2016;137:168-78.
7. Varricchi G, Raap U, Rivellese F, Marone G, Gibbs BF. Human mast cells and basophils. How are they similar, how are they different? Immunol Rev. 2018;282(1):8-34.
8. Reber LL, Sibilano R, Mukai K, Galli SJ. Potential effector and immunoregulatory functions of mast cells in mucosal immunity. Mucosal Immunol. 2015;8(3):444-63.
9. Gri G, Frossi B, D'Inca F, Danelli L, Betto E, Mion F, et al. Mast cell: an emerging partner in immune interaction. Front Immunol. 2012;3:120-2.
10. Abraham SN, St John AL. Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol. 2010;10:440-52.
11. da Silva EZ, Jamur MC, Oliver C. Mast cell function: a new vision of an old cell. J Histochem Cytochem. 2014;62:698-738.
12. Migalovich-Sheikhet H, Friedman S, Mankuta D, Levi-Schaffer F. Novel identified receptors on mast cells. Front Immunol. 2012;3:238‑42.
13. Gilfillan AM, Beaven MA. Regulation of mast cell responses in health and disease. Crit Rev Immunol. 2011;31(6):475-529.
14. Halova I, Draberova L, Draber P. Mast cell chemotaxis-chemoattractants and signaling pathways. Front Immunol. 2012;3:119.
15. Varricchi G, Rossi FW, Galdiero MR, Granata F, Criscuolo G, Spadaro G, et al. Physiological Roles of Mast Cells: Collegium Internationale Allergologicum Update 2019. Int Arch Allergy Immunol. 2019;17:247-61.
16. Galli SJ, Borregaard N, Wynn TA. Phenotypic and functional plasticity of cells of innate immunity: macrophages, mast cells and neutrophils. Nat Immunol. 2011;12:1035-44.
17. Rottem M, Mekori YA. Mast cells and autoimmunity. Autoimmun Rev. 2005;4:21-7.
18. Bachelet I, Levi-Schaffer F, Mekori YA. Mast cells: not only in allergy. Immunol Allergy Clin North Am. 2006;26:407-25.
19. Theoharides TC, Tsilioni I, Bawazeer M. Mast Cells, Neuroinflammation and Pain in Fibromyalgia Syndrome. Front Cell Neurosci. 2019;13:353.
20. Galli SJ, Grimbaldeston M, Tsai M. Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nat Rev Immunol. 2008;8:478-86.
21. Theoharides T, Tsilionia I, Rene H. Recent advances in our understanding of mast cell activation - or should it be mast cell mediator disorders? Expert Rev Clin Immunol. 2019;15(6):639‑56.
22. Flores JA, Balseiro-Gomez S, Ales E. Emerging Roles of Granule Recycling in Mast Cell Plasticity and Homeostasis. Crit Rev Immunol. 2016;36(6):461-84.
23. Weiler CR. Mast Cell Activation Syndrome: Tools for Diagnosis and Differential Diagnosis. J Allergy Clin Immunol Practice. 2019;8:498‑507.
24. Valent P, Akin C, Arock M, Brockow K, Butterfield JH, Carter MC, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol. 2012;157:215-25.
25. Valent P, Akin C, Bonadonna P, Hartmann K, Brockow K, Niedoszytko M. Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome. J Allergy Clin Immunol Pract. 2019;7(4):1125-33.
26. Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome: proposed diagnostic criteria. J Allergy Clin Immunol. 2010;126:1099‑104.
27. Valent P, Akin C, Nedoszytko B, Bonadonna P, Hartmann K, Niedoszytko M, et al. Diagnosis, Classification and Management of Mast Cell Activation Syndromes (MCAS) in the Era of Personalized Medicine. Int J Mol Sci. 2020;21:9030.
28. Valent P, Akim C, Hartmann K, Alvarez-Twose I, Brockow K, Hermine O. Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal. Hemasphere. 2021;13,5(11):e646.
29. Afrin LB, Butterfield JH, Ralthel M, Molderings GJ. Often seen, rarely recognized: mast cell activation disease - a guide to diagnosis and therapeutic options. Ann Med. 2016;48:190-201.
30. Rama TA, Moreira A, Delgado L. Abordagem diagnóstica e terapêutica das mastocitoses - Uma proposta de orientação clínica. Rev Port Imunoalergologia. 2020;28(1):31-49.
31. Nurmatov UB, Rhatigan E, Simons FE, Sheikh A. H1-antihistamines for primary mast cell activation syndromes: a systematic review. Allergy. 2015;70:1052-61.
32. Siebenhaar F, Fortsch A, Krause K, Weller K, Metz M, Magerl M, et al. Rupatadine improves quality of life in mastocytosis: a randomized, double-blind, placebo-controlled trial. Allergy. 2013;68:949-52.
33. Mullol J, Bousquet J, Bachert C, Canonica GW, Gimenez-Arnau A, Kowalski ML, et al. Update on rupatadine in the management of allergic disorders. Allergy. 2015;70 Suppl 100:1-24.
34. Mullol J, Muñoz-Cano R, Torres-Atencio I, Ainsua E, Martin M, Sanchez-Lopez J, et al. Platelet activating factor-induced mast cell degranulation is inhibited by rupatadine, and to a lower extent by levocetirizine and desloratadine, in a mast cell line (LAD-2). Clin Transl Allergy. 2013;3(Suppl 2):O6.
35. Weller K, Maurer M. Desloratadine Inhibits Human Skin Mast Cell Activation and Histamine Release. J Invest Dermatol. 2009;129:2723-6.
36. Matito A, Escribese MM, Longo N, Mayorga C, Luengo-Sánchez O, Pérez-Gordo M, et al.; Comité de Inmunología de la Sociedad Española de Alergología e Inmunología Clínica (SEAIC). Clinical Approach to Mast Cell Activation Syndrome: A Practical Overview. J Investig Allergol Clin Immunol. 2021;31(6):461-70.
37. Lemal R, Fouquet G, Terriou L, Vaes M, Livideanu CB, Frenzel L, et al. Omalizumab Therapy for Mast Cell-Mediator Symptoms in Patients with ISM, CM, MMAS, and MCAS. J Allergy Clin Immunol Pract. 2019;7:2387-95.
38. Giannetti A, Filice E, Caffarelli C, Ricci G, Pession A. Mast Cell Activation Disorders. Medicina (Kaunas). 2021;57:124.
39. González-de-Olano D, Padial-Vilchez MA, Núñez-Acevedo B, de-Calzada-Bustingorri MP, de-Andrés-Martín A, Caldas C, et al. Usefulness of Omalizumab and Sting Challenge Test in Hymenoptera Venom Allergy and Mastocytosis. J Investig Allergol Clin Immunol. 2019;29:318-20.
40. Bonadonna P, Brockow K, Niedoszytko M, Gulen T, Hartmann K, Valent P. COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM). J Allergy Clin Immunol. 2021;9(6):2139-44.
41. Leru PM, Anton VF, Ureche C, Zurac S, Bratu O, Neagoe CD. Mast cell activation syndromes - evaluation of current diagnostic criteria and laboratory tools in clinical practice. Exp Ther Med. 2020;20(3):2348‑51.
Submitted date:
02/28/2022
Accepted date:
02/20/2023
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email